BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Cancer Epigenetics Society - ECPv5.3.2.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Cancer Epigenetics Society
X-ORIGINAL-URL:https://ces.b2sg.org
X-WR-CALDESC:Events for Cancer Epigenetics Society
BEGIN:VTIMEZONE
TZID:Europe/Paris
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20190331T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20191027T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20190329
DTEND;VALUE=DATE:20190404
DTSTAMP:20260729T142808
CREATED:20181010T135414Z
LAST-MODIFIED:20181011T070426Z
UID:20732-1553817600-1554335999@ces.b2sg.org
SUMMARY:AACR Annual Meeting 2019
DESCRIPTION:Integrative Cancer Science • Global Impact • Individualized Patient Care \nFriday\, March 29-Wednesday\, April 3\, 2019\nGeorgia World Congress Center\nAtlanta\, Georgia \n  \nProgram Committee Chair\nJohn D. Carpten\, USC Keck School of Medicine\, Los Angeles\, California \n\nDownload the Call for Abstracts\nAbstract Submission Deadline: Thursday\, Nov. 15\, 2018\, 11:59 p.m. ET\nLate-Breaking and Clinical Trials Abstract Submission Deadline: Thursday\, Jan. 10\, 2019\, 11:59 p.m. ET\nHousing Deadline: Wednesday\, Feb. 13\, 2019\nEarly Registration Deadline: Friday\, Dec. 7\, 2018\, 11:59 p.m. ET\n\nThe AACR Annual Meeting program covers the latest discoveries across the spectrum of cancer research—from population science and prevention; to cancer biology\, translational\, and clinical studies; to survivorship and advocacy—and highlights the work of the best minds in research and medicine from institutions all over the world.  More information about the AACR Annual Meeting 2019 will be available online and in the Call for Abstracts in late August 2018.  \nProgram Committee Vice Chairs\nKenneth C. Anderson\, Dana-Farber Cancer Institute\, Boston\, Massachusetts\nMarcia R. Cruz-Correa\, University of Puerto Rico Comprehensive Cancer Center\, San Juan\, Puerto Rico\nTodd R. Golub\, Broad Institute of MIT and Harvard\, Cambridge\, Massachusetts\nStephen D. Hursting\, University of North Carolina at Chapel Hill\, Chapel Hill\, North Carolina\nPatricia M. LoRusso\, Yale Cancer Center\, New Haven\, Connecticut\nRichard M. Marais\, Cancer Research UK Manchester Institute\, Manchester\, United Kingdom\nAviv Regev\, Massachusetts Institute of Technology and Broad Institute of MIT and Harvard\, Cambridge\, Massachusetts\nAntoni Ribas\, UCLA Medical Center\, Los Angeles\, California\nBrian M. Rivers\, Morehouse School of Medicine\, Atlanta\, Georgia\nDavid A. Tuveson\, Cold Spring Harbor Laboratory Cancer Center\, Cold Spring Harbor\, New York \nProgram Committee Cochairs\nNilofer S. Azad\, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center\, Baltimore\, Maryland\nAnna D. Barker\, Arizona State University\, Scottsdale\, Arizona\nJulian Blagg\, Institute of Cancer Research\, Sutton\, Surrey\, United Kingdom\nJohn M. Carethers\, University of Michigan\, Ann Arbor\, Michigan\nLouis Chesler\, Institute of Cancer Research\, Sutton\, United Kingdom\nDavid C. Christiani\, Harvard Medical School\, Boston\, Massachusetts\nMario P. Colombo\, Fondazione IRCCS Istituto Nazionale Tumori\, Milan\, Italy\nJoseph N. Contessa\, Yale University\, New Haven\, Connecticut\nLisa M. Coussens\, OHSU Knight Cancer Institute\, Portland\, Oregon\nDavid W. Craig\, USC Keck School of Medicine\, Los Angeles\, California\nChristina Curtis\, Stanford University\, Stanford\, California\nRiccardo Dalla-Favera\, Columbia University Institute for Cancer Genetics\, New York\, New York\nCaroline Dive\, Cancer Research UK Manchester Institute\, Manchester\, United Kingdom\nLaura Fejerman\, University of California\, San Francisco\, San Francisco\, California\nKevin L. Gardner\, Columbia University\, New York\, New York\nDavid R. Gius\, Northwestern University\, Chicago\, Illinois\nMithat Gönen\, Memorial Sloan Kettering Cancer Center\, New York\, New York\nJennifer Rubin Grandis\, University of California\, San Francisco\, San Francisco\, California\nJohn D. Groopman\, Johns Hopkins University School of Public Health\, Baltimore\, Maryland\nSusan E. Hankinson\, University of Massachusetts Amherst\, Amherst\, Massachusetts\nJamie N. Holloway\, Georgetown University\, Washington\, District of Columbia\nCatriona H.M. Jamieson\, UCSD Moores Cancer Center\, La Jolla\, California\nPeter Kuhn\, University of Southern California\, Los Angeles\, California\nSherene Loi\, Peter MacCallum Cancer Centre\, Camberwell\, Victoria\, Australia\nThomas J. Lynch\, Jr.\, Bristol-Myers Squibb Co.\, New York\, New York\nCrystal L. Mackall\, Stanford University School of Medicine\, Stanford\, California\nTak W. Mak\, Campbell Family Institute for Breast Cancer Research\, Toronto\, Ontario\, Canada\nHiroyuki Mano\, National Cancer Center Research Institute\, Tokyo\, Japan\nGordon B. Mills\, OHSU Knight Cancer Institute\, Portland\, Oregon\nLisa A. Newman\, Henry Ford Health System\, Detroit\, Michigan\nKunle Odunsi\, Roswell Park Cancer Institute\, Buffalo\, New York\nMoshe Oren\, Weizmann Institute of Science\, Rehovot\, Israel\nKlaus Pantel\, University Medical Center Hamburg\, Hamburg\, Germany\nWilliam Pao\, Roche Pharma Research and Early Development\, Basel\, Switzerland\nLuis F. Parada\, Memorial Sloan Kettering Cancer Center\, New York\, New York\nElectra D. Paskett\, Ohio State University Comprehensive Cancer Center\, Columbus\, Ohio\nEdith A. Perez\, Genentech\, Inc.\, South San Francisco\, California\nEric H. Rubin\, Merck Research Laboratories\, North Wales\, Pennsylvania\nAnil K. Rustgi\, University of Pennsylvania School of Medicine\, Philadelphia\, Pennsylvania\nPatty Spears\, UNC Lineberger Comprehensive Cancer Center\, Chapel Hill\, North Carolina\nVictor E. Velculescu\, Sidney Kimmel Comprehensive Cancer Center and Johns Hopkins University School of Medicine\, Baltimore\, Maryland\nJennifer A. Wargo\, The University of Texas MD Anderson Cancer Center\, Houston\, Texas\nE. John Wherry III\, University of Pennsylvania\, Philadelphia\, Pennsylvania\nLouis M. Weiner\, Georgetown Lombardi Comprehensive Cancer Center\, Washington\, District of Columbia \n  \nAbout the Location\nAtlanta\, the capital of and the most populous city in Georgia\, is a cultural and economic center of the state and the ninth largest metropolitan area in the United States. The city is the primary transportation hub of the Southeastern United States\, via highway\, railroad\, and air\, with Hartsfield–Jackson Atlanta International Airport being the world’s busiest airport since 1998. Atlanta is home to nationally renowned private colleges and universities\, most notably Emory University\, a leading liberal arts and research institution that ranks among the top 20 schools in the United States. Emory University – home to Winship Cancer Institute – also operates Emory Healthcare\, the largest health care system in Georgia.
URL:https://ces.b2sg.org/event/aacr-29mar19/
LOCATION:Georgia World Congress Center\, 285 Andrew Young International Blvd NW\, Atlanta\, GA\, 30313\, United States
CATEGORIES:Meetings
ATTACH;FMTTYPE=image/jpeg:https://ces.b2sg.org/wp-content/uploads/2018/10/aacr-2019.jpg
END:VEVENT
END:VCALENDAR